Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Aligos Therapeutics
- Telefonní číslo: 800-466-6059
- E-mail: info@aligos.com
Studijní místa
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53704
- Aligos Investigational Site
-
Kontakt:
- Aligos Investigational Site
- Telefonní číslo: 800-466-6059
- E-mail: info@aligos.com
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria: Key Inclusion Criteria
- Parts A and B only: Male or female between 18 and 60 years of age
- Part C only: Males between 18 and 55 years of age.
- Body mass index between 18.0 kg/m2 and 32.0 kg/m2
- In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
- Part C only: History of a minimum of 1 bowel movement per day.
Exclusion Criteria: Key Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
-
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Parts A and B only: Any of the following at screening or check-in:
- QTcF >450 ms in males or >470 ms in females
- QRS duration >120 ms
- PR interval >210 ms
- findings which would make QTc measurements difficult or QTc data uninterpretable
-
Administration of any vaccine within 30 days prior to dosing.
-
Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
-
Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
-
Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of ALG-000184 |
|
Komparátor placeba: Placebo
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of Placebo |
|
Jiný: [14C]ALG-000184
|
Single oral dose of [14C]ALG-000184 Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184 |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Safety and Tolerability (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2 |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including ARAUC |
From enrollment to end of treatment at 10 days
|
|
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Metabolic profiles of ALG-000184 (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Identification of ALG-000184 (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Bioavailability of ALG-001075 (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075 |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2 |
From enrollment to end of treatment at 10 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
QTc (Part A and B)
Časové okno: From enrollment to end of treatment at 10 days
|
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants |
From enrollment to end of treatment at 10 days
|
|
Safety and Tolerability (Part C)
Časové okno: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
Další identifikační čísla studie
- ALG-000184-209
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .